InsiderTrades.com logo
Nathan L. Mata net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Nathan Mata Biography and Net Worth

Chief Scientific Officer of Belite Bio

Dr. Nathan L. Mata has served as the Chief Scientific Officer of Belite Bio since November 2021. Prior to joining Belite Bio, Dr. Mata was the principal consultant of clinical development sector of Halloran Consulting Group, clinical research and operations consultant of Kubota Vision Inc. (formerly Acucela Inc.), Chief Operating Officer and Director of R&D of  Trethera Corporation, and Vice President of R&D of Sirion Therapeutics. Dr. Mata received his master’s degree in Biochemistry and PhD in Neurobiology from University of Texas at San Antonio.

What is Nathan L. Mata's net worth?

The estimated net worth of Nathan L. Mata is at least $2.58 million as of April 15th, 2026. Dr. Mata owns 15,666 shares of Belite Bio stock worth more than $2,581,443 as of April 17th. This net worth evaluation does not reflect any other assets that Dr. Mata may own. Learn More about Nathan L. Mata's net worth.

How do I contact Nathan L. Mata?

The corporate mailing address for Dr. Mata and other Belite Bio executives is , , . Belite Bio can also be reached via phone at 858-246-6240 and via email at [email protected]. Learn More on Nathan L. Mata's contact information.

Has Nathan L. Mata been buying or selling shares of Belite Bio?

Within the last three months, Nathan L. Mata has sold $168,300.00 of Belite Bio stock. Most recently, Nathan L. Mata sold 1,000 shares of the business's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $168.30, for a transaction totalling $168,300.00. Following the completion of the sale, the insider now directly owns 15,666 shares of the company's stock, valued at $2,636,587.80. Learn More on Nathan L. Mata's trading history.

Are insiders buying or selling shares of Belite Bio?

In the last year, insiders at the sold shares 4 times. They sold a total of 17,500 shares worth more than $3,161,413.00. The most recent insider tranaction occured on April, 15th when insider Nathan L Mata sold 1,000 shares worth more than $168,300.00. Insiders at Belite Bio own 13.3% of the company. Learn More about insider trades at Belite Bio.

Information on this page was last updated on 4/15/2026.

Nathan L. Mata Insider Trading History at Belite Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/15/2026Sell1,000$168.30$168,300.0015,666View SEC Filing Icon  
See Full Table

Nathan L. Mata Buying and Selling Activity at Belite Bio

This chart shows Nathan L Mata's buying and selling at Belite Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Belite Bio Company Overview

Belite Bio logo
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Read More

Today's Range

Now: $165.45
Low: $158.10
High: $165.71

50 Day Range

MA: $171.04
Low: $149.18
High: $190.30

2 Week Range

Now: $165.45
Low: $53.60
High: $200.00

Volume

171,754 shs

Average Volume

203,901 shs

Market Capitalization

$6.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A